Fyn kinase mediates the development of rats with chronic obstructive pulmonary disease by modulating the activation of p38 MAPK and NF-κB

Document Type : Original Article

Authors

1 Department of Geriatric Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China

2 Department of General Practice, The Third Affiliated Hospital of Anhui Medical University, Hefei, 230061, Anhui, China

3 Bengbu Medical University, Bengbu, 233030, Anhui, China

4 Department of Critical Care Medicine, The Third Affiliated Hospital of Anhui Medical University, Hefei, 230061, Anhui, China

5 The Third Affiliated Hospital of Anhui Medical University, Hefei, 230061, Anhui, China

10.22038/ijbms.2025.82400.17818

Abstract

Objective(s): The current research was conducted to study the function of Fyn in a rat model of chronic obstructive pulmonary disease (COPD).
Materials and Methods: COPD in rats was induced by intratracheal instillation of lipopolysaccharide and long-term exposure to cigarette smoke. Subsequently, the rats were treated with the Fyn-specific inhibitor AZD0530. Pulmonary function, pathological appearance, and inflammatory factors were assessed in rats with COPD.
Results: AZD0530 significantly ameliorated pulmonary function and improved the pathological manifestations of COPD in rats. AZD0530 decreased MCP-1 and CD68 expression in lung tissues, reduced inflammatory cell accumulation, and decreased TNF-α and IL-6 production in bronchoalveolar lavage fluid. In an in vitro study, pharmacological inhibition of Fyn or knockdown of Fyn by siRNA inhibited lipopolysaccharide- and cigarette smoke extract-induced TNF-α and IL-6 secretion in the human bronchial epithelial cell line BEAS-2B. Furthermore, inhibition of Fyn by either the inhibitor or siRNA Fyn reduced the phosphorylation of p38 MAPK- and NF-κB-related molecules, which strongly affected the occurrence of inflammatory responses.
Conclusion: Collectively, these data show that Fyn promotes COPD development by modulating the p38 MAPK and NF-κB signaling pathways. Fyn might be a promising therapeutic target for COPD.

Keywords

Main Subjects

References

1. Zhang X, Lei Z, Wu Y, Song Y, Wu X, Yang B, et al. Prevalence and risk factors for COPD in an urbanizing rural area in western china: A cross-sectional study. Int J Chron Obstruct Pulmon Dis 2023; 18: 459-468.
2. Riley CM, Sciurba FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: A review. JAMA 2019; 321: 786-797.
3. Ma J, Tian Y, Li J, Zhang L, Wu M, Zhu L, et al. Effect of bufei yishen granules combined with electroacupuncture in rats with chronic obstructive pulmonary disease via the regulation of TLR-4/NF-κB signaling. Evid Based Complement Alternat Med 2019; 2019: 6708645-6708659.
4. Dong YH, Hsu CL, Li YY, Chang CH, Lai MS. Bronchodilators use in patients with COPD. Int J Chron Obstruct Pulmon Dis 2015; 10: 1769-1779.
5. Woods JA, Wheeler JS, Finch CK, Pinner NA. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 421-430.
6. Guo P, Li R, Piao TH, Wang CL, Wu XL, Cai HY. Pathological mechanism and targeted drugs of COPD. Int J Chron Obstruct Pulmon Dis 2022; 17: 1565-1575.
7. Benjamin JT, Plosa EJ, Sucre JM, van der Meer R, Dave S, Gutor S, et al. Neutrophilic inflammation during lung development disrupts elastin assembly and predisposes adult mice to COPD. J Clin Invest 2021; 131: e139481-139497.
8. Peng S, Fu Y. FYN: Emerging biological roles and potential therapeutic targets in cancer. J Transl Med 2023; 21: 84-101.
9. Lee D, Park YH, Lee JE, Kim HS, Min KY, Jo MG, et al. Dasatinib inhibits Lyn and Fyn Src- family kinases in mast cells to suppress type I hypersensitivity in mice. Biomol Ther (Seoul) 2020; 28: 456-464.
10. Saminathan H, Charli A, Luo J, Panicker N, Gordon R, Hostetter JM, et al. Fyn kinase mediates proinflammatory response in a mouse model of endotoxemia: Relevance to translational research. Eur J Pharmacol 2020 ; 881: 173259-173280.
11. Sakai H, Nishimura A, Watanabe Y, Nishizawa Y, Hashimoto Y, Chiba Y, et al. Involvement of Src family kinase activation in angiotensin II-induced hyperresponsiveness of rat bronchial smooth muscle. Peptides 2010; 31: 2216-2221.
12. Wang X, Hao Y, Yin Y, Hou Y, Han N, Liu Y, et al. Lianhua qingke preserves mucociliary clearance in rat with acute exacerbation of chronic obstructive pulmonary disease by maintaining ciliated cells proportion and protecting structural integrity and beat function of cilia. Int J Chron Obstruct Pulmon Dis 2024; 19: 403-418.
13. He Y, Wang S, Li Y, Deng J, Huang L. Effects of atorvastatin in suppressing pulmonary vascular remodeling in rats with chronic obstructive pulmonary disease. Clinics (Sao Paulo) 2023; 78: 100252-100259.
14. Li Q, Sun J, Cao Y, Liu B, Li L, Mohammadtursun N, et al. Bu-Shen-Fang-Chuan formula attenuates T-lymphocytes recruitment in the lung of rats with COPD through suppressing CXCL9/ CXCL10/ CXCL11 -CXCR3 axis. Biomed Pharmacother 2020; 123: 109735-109745.
15. Xu Y, Li J, Lin Z, Liang W, Qin L, Ding J, et al. Isorhamnetin alleviates airway inflammation by regulating the Nrf2/Keap1 pathway in a mouse model of COPD. Front Pharmacol 2022; 13: 860362-860378.
16. Zhang H, Liu B, Jiang S, Wu JF, Qi CH, Mohammadtursun N, et al. Baicalin ameliorates cigarette smoke -induced airway inflammation in rats by modulating HDAC2/NF-κB/PAI-1 signalling. Pulm Pharmacol Ther 2021; 70: 102061.
17. Li J, Xie Y, Zhao P, Qin Y, Oliver BG, Tian Y, et al. A chinese herbal formula ameliorates COPD by inhibiting the inflammatory response via downregulation of p65, JNK, and p38. Phytomedicine 2021; 83: 153475-153486.
18. Duan J, Yang Z, Huang J, Zhu Y, Zhao H, Unwith S, et al. Inhibition of tyrosine kinases protects against lipopolysaccharide-induced acute lung injury by preventing nuclear export of Nrf2. J Cell Biochem 2019; 120: 12331-12339.
19. Anidi IU, Servinsky LE, Rentsendorj O, Stephens RS, Scott AL, Pearse DB. CD36 and Fyn kinase mediate malaria-induced lung endothelial barrier dysfunction in mice infected with Plasmodium berghei. PLoS One 2013; 8: e71010-71023.
20. Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, et al. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol 2009; 4: 448-454.
21. Van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, et al. Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: A randomized clinical trial. JAMA Neurol 2019; 76: 1219-1229.
22. Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 2009; 3: 248-261.
23. Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 2010; 16: 4876-4883.
24. Molina JR, Foster NR, Reungwetwattana T, Nelson GD, Grainger AV, Steen PD, et al. A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer 2014; 85: 245-250.
25.  Guo P, Li R, Piao TH, Wang CL, Wu XL, Cai HY. Pathological mechanism and targeted drugs of COPD. Int J Chron Obstruct Pulmon Dis 2022; 17: 1565-1575.
26. Chen XR, Wang DX. Serum MCP-1 and NGAL Play an important role in the acute inflammatory event of chronic obstructive pulmonary disease. COPD 2021; 18: 425-431.
27. Li N, Liu Y, Cai J. LncRNA MIR155HG regulates M1/M2 macrophage polarization in chronic obstructive pulmonary disease. Biomed Pharmacother 2019; 117: 109015-109023.
28. Huang H, Feng H, Zhuge D. M1 macrophage activated by notch signal pathway contributed to ventilator-induced lung injury in chronic obstructive pulmonary disease model. J Surg Res 2019; 244: 358-367.
29. Caramori G, Adcock IM, Di Stefano A, Chung KF. Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 397-412.
30. Saminathan H, Charli A, Luo J, Panicker N, Gordon R, Hostetter JM, et al. Fyn kinase mediates proinflammatory response in a mouse model of endotoxemia: Relevance to translational research. Eur J Pharmacol 2020; 881: 173259-173280.
31. Dong D, Zhang Y, He H, Zhu Y, Ou H. Alpinetin inhibits macrophage infiltration and atherosclerosis by improving the thiol redox state: Requirement of GSk3β/Fyn-dependent Nrf2 activation. FASEB J 2022; 36: e22261-22277.
32. Uddin MJ, Dorotea D, Pak ES, Ha H. Fyn kinase: A potential therapeutic target in acute kidney injury. Biomol Ther (Seoul) 2020; 28: 213-221.
33. Wang T, Zhang X, Li JJ. The role of NF-kappaB in the regulation of cell stress responses. Int Immunopharmacol 2002; 2: 1509-1520.
34. Kulms D, Schwarz T. NF-kappaB and cytokines. Vitam Horm 2006; 74: 283-300.
35. Khan MA, Rabbani G, Kumari M, Khan MJ. Ellagic acid protects type II collagen induced arthritis in rat via diminution of IKB phosphorylation and suppression IKB-NF-kB complex activation: In vivo and in silico study. Inflammopharmacology 2022; 30: 1729-1743.
36. Du G, Wang J, Zhang T, Ding Q, Jia X, Zhao X, et al.Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo. Cell Death Dis 2020 ;11:118-130.
Iranian Journal of Basic Medical Sciences
Volume 28, Issue 7
July 2025
Pages 880-887

Files

Share

How to cite

Statistics